Cumberland Pharma updates Phase 2 FIGHT DMD trial data showing 5.4% LVEF gain with ifetroban in Duchenne cardiomyopathy

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

CPIX

0.00
  • Cumberland Pharmaceuticals presented updated Phase 2 FIGHT DMD trial results for ifetroban at the Parent Project Muscular Dystrophy annual conference.
  • Data reinforced earlier findings of improved heart function in Duchenne muscular dystrophy patients, supported by blood markers consistent with reduced heart injury.
  • Longer follow-up from the open-label extension indicated a favorable safety profile with no treatment-related serious adverse events or new safety concerns.
  • Ifetroban targets Duchenne-related cardiomyopathy, a major unmet need with no approved therapies specifically for the underlying cardiac disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606261100PR_NEWS_USPR_____CL93221) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.